Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer

被引：0
|
作者：
Govindan, R. [1 ]
Fakih, M. [2 ]
Price, T. [3 ]
Falchook, G. [4 ]
Desai, J. [5 ]
Kuo, J. [6 ]
Strickler, J. [7 ]
Krauss, J. [8 ]
Li, B. [9 ]
Denlinger, C. [10 ]
Durm, G. [11 ]
Ngang, J. [12 ]
Henary, H. [12 ]
Ngarmchamnanrith, G. [12 ]
Rasmussen, E. [12 ]
Morrow, P. K. [12 ]
Hong, D. [13 ]
机构：
[1] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Queen Elizabeth Hosp, Woodville South, Australia
[4] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] Scientia Clin Res, Randwick, NSW, Australia
[7] Duke Univ, Med Ctr, Durham, NC 27706 USA
[8] Univ Michigan, Ann Arbor, MI 48109 USA
[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[11] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[12] Amgen Inc, Thousand Oaks, CA 91320 USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
AMG; 510; lung cancer; KRAS G12C; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA01.06
引用
收藏
页码：S1125 / S1126
页数：2
相关论文
共 50 条
  • [41] The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
    Hu, Xingsheng
    Lin, Lin
    Xing, Puyuan
    Zhang, Changgong
    Wang, Lin
    Liz, Yiqun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S902 - S902
  • [42] Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR
    Li, Jinsong
    Deng, Huayun
    Hu, Meichun
    Fang, Yuanzhang
    Vaughn, Amanda
    Cai, Xiaopan
    Xu, Lequin
    Wan, Wei
    Li, Zhenxi
    Chen, Shijie
    Yang, Xinghai
    Wu, Song
    Xiao, Jianru
    ONCOTARGET, 2015, 6 (09) : 6749 - 6761
  • [43] A novel small inhibitor, LLL12, targets STAT3 in non-small cell lung cancer in vitro and in vivo
    Nie, Yanli
    Li, Yuanyuan
    Hu, Sheng
    ONCOLOGY LETTERS, 2018, 16 (04) : 5349 - 5354
  • [44] The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
    Wang, Jijin
    Huang, Di
    Yang, Wenjing
    Song, Qingxu
    Jia, Yibin
    Chen, Pengxiang
    Cheng, Yufeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety
    Shao, Lan
    Lou, Guangyuan
    JOURNAL OF THORACIC DISEASE, 2022, 14 (09)
  • [46] Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
    Zheng, Xinting
    Luo, Jiamin
    Liu, Wei
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    Lin, Lizhu
    DRUGS OF TODAY, 2022, 58 (04) : 175 - 185
  • [47] Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes
    Caballe, E.
    Hernandez-Pedro, N.
    Ramos-Ramirez, M.
    Romero-Nunez, E.
    Lucio-Lozada, J.
    Barrios-Bernal, P.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S196 - S197
  • [48] Chemotherapy of advanced non-small cell lung cancer in elderly patients
    Rossi, A
    Gridelli, C
    ANNALS OF ONCOLOGY, 2006, 17 : 58 - 60
  • [49] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [50] Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older
    Saito, Zentaro
    Fujita, Kohei
    Okamura, Misato
    Ito, Takanori
    Yamamoto, Yuki
    Kanai, Osamu
    Hashimoto, Masayuki
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    CANCER REPORTS, 2021, 4 (06)
12345